LabCorp announced the availability of Epi proColon, a blood-based test for colorectal cancer screening.
Epi proColon, developed by Epigenomics, was approved by the Food and Drug Administration (FDA) in April 2016 as the first DNA-based blood test for colorectal cancer. The test requires a small blood draw and serves as an alternative for patients who are unwilling or unable to be screened by recommended methods (eg, stool sample, colonoscopy).
Epi proColon works by detecting Epigenomics’ proprietary Septin9 DNA methylation biomarker for colorectal cancer in cell-free DNA circulating in the blood. Multiple clinical studies have shown this to be a reliable indicator of the presence of colorectal cancer. This biomarker can be detected in tumor DNA that has been shed into the bloodstream from proximal and distal colon and rectal sites, making it a differential biomarker for early detection.
The test does not require pretest dietary or medication restriction prior to blood draw. Patients with positive results should be referred for diagnostic colonoscopy. Epi proColon is available immediately from LabCorp.
For more information visit EpiproColon.com.